Eli Lilly's stock, once soaring, has recently faced a downturn due to various factors. Despite these challenges, the prevailing sentiment among Wall Street analysts remains highly optimistic regarding the pharmaceutical giant's future prospects. This article delves into the reasons behind the stock's recent decline and examines why experts on Wall Street continue to express strong confidence in Lilly's trajectory, highlighting that the company's underlying strengths appear to outweigh its current difficulties.
For a period, it seemed Eli Lilly was on an unstoppable ascent, driven by robust sales of its type 2 diabetes medication, Mounjaro, and high expectations for its obesity drug, Zepbound. This propelled Lilly to become the largest healthcare company globally by market capitalization. However, since the summer of 2025, the company's stock performance has faltered, with its share price dropping over 20% from its peak. This significant decline has prompted questions among investors about whether to abandon the stock that once showed such promising growth. Nevertheless, the investment community largely advises against bailing out.
Several elements have contributed to the recent sell-off. One major concern among investors is the intensifying competition within the obesity drug sector. This worry was amplified by positive early-stage clinical trial results for an oral GLP-1 receptor agonist, CT-996, developed by Roche. Additionally, Lilly's recent financial reports have not consistently met expectations. The first quarter of 2025 saw the company revise its earnings forecast downward, following sales figures for Mounjaro and Zepbound in the preceding two quarters that fell short of projections.
Further dampening spirits were the results from the initial phase 3 study of orforglipron, an experimental oral GLP-1 drug. Although the highest dosage led to a significant 11.5% placebo-adjusted weight loss, this outcome did not fully align with analysts' expectations. The higher discontinuation rate of 10.3% for the 36-milligram dose due to adverse events, compared to just 2.6% for the placebo group, also caused some disappointment. Political factors have also played a role, with former President Trump's administration potentially imposing substantial tariffs on pharmaceutical imports to the U.S., which Lilly's CEO, Dave Ricks, noted would negatively impact the company and the broader industry.
Despite these headwinds, Wall Street analysts largely maintain a bullish stance on Eli Lilly. This confidence is evident in two key areas. Firstly, a recent S&P Global survey of 28 analysts showed that 20 rated Lilly's stock as either a 'buy' or 'strong buy,' with the remaining eight recommending a 'hold.' Notably, there were no 'sell' recommendations in the latest survey, a shift from just a few months prior when two analysts had suggested selling. Secondly, the average 12-month price target for Lilly indicates an approximate 19% upside potential. Some analysts are even more optimistic, with Citigroup forecasting a nearly 59% jump, and JPMorgan Chase, Morgan Stanley, and Wells Fargo anticipating at least a 46% increase.
While the exact timing and magnitude of future gains remain uncertain, the overall positive outlook for Eli Lilly is well-founded. Both Mounjaro and Zepbound continue to offer substantial sales growth potential, particularly with Mounjaro showing promise in cardiovascular benefits from a phase 3 study. Furthermore, the experimental drug orforglipron is still expected to achieve significant commercial success, given the high demand for effective oral weight-loss solutions. The recent insider buying by CEO Dave Ricks and other key executives and board members also signals a strong belief in the company's future, adding a layer of confidence for investors.